Literature DB >> 26300515

Use of sevelamer in chronic kidney disease: beyond phosphorus control.

Laura Rodríguez-Osorio1, Diana Pazmiño Zambrano1, Carolina Gracia-Iguacel1, Jorge Rojas-Rivera1, Alberto Ortiz2, Jesus Egido2, Emilio González Parra3.   

Abstract

Sevelamer is a non-calcium phosphate binder used in advanced chronic kidney disease (CKD) and in dialysis for hyperphosphataemia control. Several experimental, observational studies and clinical trials have shown that sevelamer has pleiotropic effects, beyond hyperphosphataemia control, including actions on inflammation, oxidative stress, lipid profile and atherogenesis, vascular calcification, endothelial dysfunction and the reduction of several uremic toxins. This is the biological basis for its global effect on cardiovascular morbidity and mortality in patients with chronic kidney disease. This review focuses on these pleiotropic actions of sevelamer and their impact on cardiovascular health, with the experience published after more than ten years of clinical expertise.
Copyright © 2015. Published by Elsevier España, S.L.U.

Entities:  

Keywords:  Efectos pleiotrópicos; Fósforo; Gut; Inflamación e intestino; Inflammation; Phosphate; Pleiotropic effects; Sevelamer

Mesh:

Substances:

Year:  2015        PMID: 26300515     DOI: 10.1016/j.nefro.2015.05.022

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  7 in total

1.  Sevelamer reduces endothelial inflammatory response to advanced glycation end products.

Authors:  Paulo C Gregório; Giane Favretto; Guilherme L Sassaki; Regiane S Cunha; Alessandra Becker-Finco; Roberto Pecoits-Filho; Wesley M Souza; Fellype C Barreto; Andréa E M Stinghen
Journal:  Clin Kidney J       Date:  2017-09-05

2.  Linkage of Fibroblast Growth Factor 23 and Phosphate in Serum: Phosphate and Fibroblast Growth Factor 23 Reduction by Increasing Dose of Sevelamer.

Authors:  Amir Ghorbanihaghjo; Hassan Argani; Zahra Golmohamadi; Nadereh Rashtchizadeh; Mehran Mesgari Abbasi; Nasrin Bargahi; Amir Mansour Vatankhah; Davoud Sanajou
Journal:  J Bone Metab       Date:  2018-08-31

Review 3.  Phosphate, Microbiota and CKD.

Authors:  Chiara Favero; Sol Carriazo; Leticia Cuarental; Raul Fernandez-Prado; Elena Gomá-Garcés; Maria Vanessa Perez-Gomez; Alberto Ortiz; Beatriz Fernandez-Fernandez; Maria Dolores Sanchez-Niño
Journal:  Nutrients       Date:  2021-04-13       Impact factor: 5.717

4.  The Influence of Sevelamer Hydrochloride and Calcium Carbonate on Markers of Inflammation and Oxidative Stress in Hemodialysis at Six Months of Follow-Up.

Authors:  Elodia Nataly Díaz-De la Cruz; José Ignacio Cerrillos-Gutiérrez; Andrés García-Sánchez; Carlos Gerardo Prado-Nevárez; Jorge Andrade-Sierra; Basilio Jalomo-Martínez; Adriana Banda-López; Enrique Rojas-Campos; Alejandra Guillermina Miranda-Díaz
Journal:  Front Med (Lausanne)       Date:  2021-11-25

5.  Sigmoid colon diverticula perforation associated with sevelamer hydrochloride administration: A case report.

Authors:  Takahisa Yamaguchi; Shigekazu Ohyama; Hiroyuki Furukawa; Nariatsu Sato; Ichiro Ohnishi; Satomi Kasashima; Atsuhiro Kawashima; Masato Kayahara
Journal:  Ann Med Surg (Lond)       Date:  2016-08-02

6.  Small steps towards the potential of 'preventive' treatment of early phosphate loading in chronic kidney disease patients.

Authors:  Jordi Bover; Mario Cozzolino
Journal:  Clin Kidney J       Date:  2019-07-25

Review 7.  The clinical impact of gut microbiota in chronic kidney disease.

Authors:  So Mi Kim; Il Han Song
Journal:  Korean J Intern Med       Date:  2020-09-29       Impact factor: 2.884

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.